vs
Apellis Pharmaceuticals, Inc.（APLS）与ENERPAC TOOL GROUP CORP（EPAC）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是ENERPAC TOOL GROUP CORP的1.4倍（$199.9M vs $144.2M），ENERPAC TOOL GROUP CORP净利率更高（13.3% vs -29.5%，领先42.8%），ENERPAC TOOL GROUP CORP同比增速更快（-0.7% vs -5.9%），ENERPAC TOOL GROUP CORP自由现金流更多（$13.3M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
恩派克工具集团前身为Actuant公司，成立于1910年，总部位于美国威斯康星州梅诺莫尼福尔斯，是一家历史悠久的工业工具企业，其普通股在纽约证券交易所上市，股票代码为EPAC。
APLS vs EPAC — 直观对比
营收规模更大
APLS
是对方的1.4倍
$144.2M
营收增速更快
EPAC
高出5.3%
-5.9%
净利率更高
EPAC
高出42.8%
-29.5%
自由现金流更多
EPAC
多$27.6M
$-14.3M
两年增速更快
APLS
近两年复合增速
2.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $144.2M |
| 净利润 | $-59.0M | $19.1M |
| 毛利率 | — | 50.7% |
| 营业利润率 | -25.6% | 19.8% |
| 净利率 | -29.5% | 13.3% |
| 营收同比 | -5.9% | -0.7% |
| 净利润同比 | -62.2% | -11.9% |
| 每股收益（稀释后） | $-0.40 | $0.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSEPAC
| Q4 25 | $199.9M | $144.2M | ||
| Q3 25 | $458.6M | $167.5M | ||
| Q2 25 | $178.5M | $158.7M | ||
| Q1 25 | $166.8M | $145.5M | ||
| Q4 24 | $212.5M | $145.2M | ||
| Q3 24 | $196.8M | $158.7M | ||
| Q2 24 | $199.7M | $150.4M | ||
| Q1 24 | $172.3M | $138.4M |
净利润APLSEPAC
| Q4 25 | $-59.0M | $19.1M | ||
| Q3 25 | $215.7M | $28.1M | ||
| Q2 25 | $-42.2M | $22.0M | ||
| Q1 25 | $-92.2M | $20.9M | ||
| Q4 24 | $-36.4M | $21.7M | ||
| Q3 24 | $-57.4M | $24.4M | ||
| Q2 24 | $-37.7M | $25.8M | ||
| Q1 24 | $-66.4M | $17.8M |
毛利率APLSEPAC
| Q4 25 | — | 50.7% | ||
| Q3 25 | — | 50.1% | ||
| Q2 25 | — | 50.4% | ||
| Q1 25 | — | 50.5% | ||
| Q4 24 | — | 51.4% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 51.8% | ||
| Q1 24 | — | 51.6% |
营业利润率APLSEPAC
| Q4 25 | -25.6% | 19.8% | ||
| Q3 25 | 48.7% | 23.8% | ||
| Q2 25 | -18.6% | 20.0% | ||
| Q1 25 | -50.0% | 21.2% | ||
| Q4 24 | -12.3% | 21.4% | ||
| Q3 24 | -24.0% | 18.9% | ||
| Q2 24 | -14.7% | 22.2% | ||
| Q1 24 | -36.0% | 21.3% |
净利率APLSEPAC
| Q4 25 | -29.5% | 13.3% | ||
| Q3 25 | 47.0% | 16.8% | ||
| Q2 25 | -23.6% | 13.9% | ||
| Q1 25 | -55.3% | 14.4% | ||
| Q4 24 | -17.1% | 15.0% | ||
| Q3 24 | -29.2% | 15.4% | ||
| Q2 24 | -18.9% | 17.1% | ||
| Q1 24 | -38.5% | 12.9% |
每股收益（稀释后）APLSEPAC
| Q4 25 | $-0.40 | $0.36 | ||
| Q3 25 | $1.67 | $0.51 | ||
| Q2 25 | $-0.33 | $0.41 | ||
| Q1 25 | $-0.74 | $0.38 | ||
| Q4 24 | $-0.30 | $0.40 | ||
| Q3 24 | $-0.46 | $0.44 | ||
| Q2 24 | $-0.30 | $0.47 | ||
| Q1 24 | $-0.54 | $0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $139.0M |
| 总债务越低越好 | — | $188.8M |
| 股东权益账面价值 | $370.1M | $431.1M |
| 总资产 | $1.1B | $818.1M |
| 负债/权益比越低杠杆越低 | — | 0.44× |
8季度趋势，按日历期对齐
现金及短期投资APLSEPAC
| Q4 25 | $466.2M | $139.0M | ||
| Q3 25 | $479.2M | $151.6M | ||
| Q2 25 | $370.0M | $140.5M | ||
| Q1 25 | $358.4M | $119.5M | ||
| Q4 24 | $411.3M | $130.7M | ||
| Q3 24 | $396.9M | $167.1M | ||
| Q2 24 | $360.1M | $132.4M | ||
| Q1 24 | $325.9M | $153.7M |
总债务APLSEPAC
| Q4 25 | — | $188.8M | ||
| Q3 25 | — | $190.0M | ||
| Q2 25 | — | $191.3M | ||
| Q1 25 | — | $192.5M | ||
| Q4 24 | — | $193.8M | ||
| Q3 24 | — | $195.0M | ||
| Q2 24 | — | $196.3M | ||
| Q1 24 | $93.1M | $245.5M |
股东权益APLSEPAC
| Q4 25 | $370.1M | $431.1M | ||
| Q3 25 | $401.2M | $433.7M | ||
| Q2 25 | $156.3M | $438.2M | ||
| Q1 25 | $164.2M | $406.0M | ||
| Q4 24 | $228.5M | $398.0M | ||
| Q3 24 | $237.1M | $392.0M | ||
| Q2 24 | $264.3M | $365.8M | ||
| Q1 24 | $266.7M | $336.9M |
总资产APLSEPAC
| Q4 25 | $1.1B | $818.1M | ||
| Q3 25 | $1.1B | $827.9M | ||
| Q2 25 | $821.4M | $828.1M | ||
| Q1 25 | $807.3M | $776.6M | ||
| Q4 24 | $885.1M | $775.4M | ||
| Q3 24 | $901.9M | $777.3M | ||
| Q2 24 | $904.5M | $749.5M | ||
| Q1 24 | $831.9M | $769.3M |
负债/权益比APLSEPAC
| Q4 25 | — | 0.44× | ||
| Q3 25 | — | 0.44× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.49× | ||
| Q3 24 | — | 0.50× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | 0.35× | 0.73× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $16.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $13.3M |
| 自由现金流率自由现金流/营收 | -7.1% | 9.2% |
| 资本支出强度资本支出/营收 | 0.1% | 1.9% |
| 现金转化率经营现金流/净利润 | — | 0.84× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $102.5M |
8季度趋势，按日历期对齐
经营现金流APLSEPAC
| Q4 25 | $-14.2M | $16.0M | ||
| Q3 25 | $108.5M | $55.3M | ||
| Q2 25 | $4.4M | $39.9M | ||
| Q1 25 | $-53.4M | $7.5M | ||
| Q4 24 | $19.4M | $8.6M | ||
| Q3 24 | $34.1M | $44.4M | ||
| Q2 24 | $-8.3M | $30.3M | ||
| Q1 24 | $-133.0M | $13.3M |
自由现金流APLSEPAC
| Q4 25 | $-14.3M | $13.3M | ||
| Q3 25 | $108.3M | $52.3M | ||
| Q2 25 | $4.4M | $35.1M | ||
| Q1 25 | $-53.4M | $1.8M | ||
| Q4 24 | $19.3M | $2.8M | ||
| Q3 24 | — | $37.9M | ||
| Q2 24 | $-8.4M | $28.5M | ||
| Q1 24 | $-133.3M | $11.7M |
自由现金流率APLSEPAC
| Q4 25 | -7.1% | 9.2% | ||
| Q3 25 | 23.6% | 31.2% | ||
| Q2 25 | 2.5% | 22.1% | ||
| Q1 25 | -32.0% | 1.2% | ||
| Q4 24 | 9.1% | 1.9% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | -4.2% | 18.9% | ||
| Q1 24 | -77.3% | 8.5% |
资本支出强度APLSEPAC
| Q4 25 | 0.1% | 1.9% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 3.1% | ||
| Q1 25 | 0.0% | 3.9% | ||
| Q4 24 | 0.0% | 4.0% | ||
| Q3 24 | 0.0% | 4.1% | ||
| Q2 24 | 0.0% | 1.2% | ||
| Q1 24 | 0.2% | 1.1% |
现金转化率APLSEPAC
| Q4 25 | — | 0.84× | ||
| Q3 25 | 0.50× | 1.97× | ||
| Q2 25 | — | 1.81× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | 1.18× | ||
| Q1 24 | — | 0.75× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EPAC
| Transferred At Point In Time | $126.0M | 87% |
| Other | $12.1M | 8% |
| Other Operating Segment | $6.1M | 4% |
